Cybin (NASDAQ:HELP) Shares Down 6.4% – Should You Sell?

06 Oct 2026, 16:02 by Danessa Lincoln · The Markets Daily

Cybin Inc. (NASDAQ:HELP – Get Free Report)’s share price was down 6.4% on Tuesday. The company traded as low as $11.04 and last traded at $10.6940. Approximately 184,840 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 1,247,016 shares. The stock had previously closed at $11.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wells Fargo & Company began coverage on Cybin in a research report on Monday, July 27th. They set an “overweight” rating and a $16.00 price target for the company. Barclays initiated coverage on Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. Wall Street Zen cut Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, TD Cowen increased their target price on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $46.33.

Check Out Our Latest Stock Analysis on HELP

Cybin Trading Down 3.5%

The firm has a market cap of $868.55 million, a PE ratio of -3.66 and a beta of 0.53. The stock’s 50 day moving average price is $11.83 and its 200 day moving average price is $7.62.

Cybin (NASDAQ:HELP – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Analysts forecast that Cybin Inc. will post -2.95 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Paul Glavine bought 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of $12.47 per share, for a total transaction of $1,247,000.00. Following the acquisition, the insider owned 4,271,252 shares in the company, valued at $53,262,512.44. This represents a 2.40% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Greg Cavers purchased 3,000 shares of Cybin stock in a transaction that occurred on Tuesday, September 29th. The shares were bought at an average cost of $12.91 per share, for a total transaction of $38,730.00. Following the completion of the transaction, the chief financial officer directly owned 3,000 shares in the company, valued at $38,730. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 688,000 shares of company stock worth $8,422,830 over the last three months. 15.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cybin

An institutional investor recently bought a new stake in Cybin stock. AXQ Capital LP acquired a new stake in Cybin Inc. (NASDAQ:HELP – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,315 shares of the company’s stock, valued at approximately $75,000. 17.94% of the stock is owned by institutional investors and hedge funds.

About Cybin

(Get Free Report)

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.